Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  8, 459 - 465 (2002)
doi:10.1038/nm0502-459

ErbB2 is essential in the prevention of dilated cardiomyopathy

Steven A. Crone1, 2, 3, 8, You-Yang Zhao2, 4, 8, Lian Fan5, Yusu Gu2, 4, Susumu Minamisawa2, 4, Yang Liu2, 4, Kirk L. Peterson2, 4, Ju Chen2, 4, Ronald Kahn6, Gianluigi Condorelli7, John Ross Jr2, 4, Kenneth R. Chien2, 4 & Kuo-Fen Lee1, 2

1  The Salk Institute, La Jolla, California, USA

2  UCSD-Salk Program in Molecular Medicine, University of California at San Diego, La Jolla, California, USA

3  Division of Biology, University of California at San Diego, La Jolla, California, USA

4  The Institute of Molecular Medicine, University of California at San Diego, La Jolla, California, USA

5  Department of Immunology, The Scripps Research Institute, La Jolla, California, USA

6  Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA

7  Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

8  S.A.C. and Y.-Y.Z. contributed equally to this study.

Correspondence should be addressed to Kuo-Fen Lee klee@salk.edu
Amplification of the gene encoding the ErbB2 (Her2/neu) receptor tyrosine kinase is critical for the progression of several forms of breast cancer. In a large-scale clinical trial, treatment with Herceptin (trastuzumab), a humanized blocking antibody against ErbB2, led to marked improvement in survival. However, cardiomyopathy was uncovered as a mitigating side effect, thereby suggesting an important role for ErbB2 signaling as a modifier of human heart failure. To investigate the physiological role of ErbB2 signaling in the adult heart, we generated mice with a ventricular-restricted deletion of Erbb2. These ErbB2-deficient conditional mutant mice were viable and displayed no overt phenotype. However, physiological analysis revealed the onset of multiple independent parameters of dilated cardiomyopathy, including chamber dilation, wall thinning and decreased contractility. Additionally, cardiomyocytes isolated from these conditional mutants were more susceptible to anthracycline toxicity. ErbB2 signaling in cardiomyocytes is therefore essential for the prevention of dilated cardiomyopathy.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

REVIEWS
Decoding calcium signals involved in cardiac growth and function
Nature Medicine Review Article (01 Nov 2000)
Organogenesis: Patterning the vertebrate heart
Nature Reviews Genetics Review (01 Jul 2002)

RESEARCH
Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart
The EMBO Journal Article (25 Feb 2004)
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
Oncogene Original Article (07 Apr 2000)
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
The EMBO Journal Article (15 May 2002)

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

Competing financial interests
Figures & Tables
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2002 Nature Publishing Group | Privacy policy